Treating with epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) accompanying lower incidence of second primary cancers

HIGHLIGHTS

• who: Wen-Ru Chou and collaborators from the Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan have published the research work: Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers, in the Journal: (JOURNAL) of 28/07/2022
• what: This study based on Taiwan`s National Health Insurance Research Database (NHIRD) a nationwide database was designed to investigate the risk factors for SPCs in patients with initial lung cancer and identify the impacts of epidermal growth factor . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.